Bio-Techne Corporation
Bio-Techne Corporation (TECH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tech · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bio-Techne Corporation (TECH) measures how much investors pay for each dollar of the company's trailing earnings. TECH's current PE ratio of 73.97x is calculated by dividing its stock price of $53.28 by its TTM earnings per share of $0.70. −6.8% discount vs 5Y avg 79.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%37.0x
MedianQ3 · 75%124.3x
Max
At 73.97x, TECH's current P/E is higher than in 85% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bio-Techne CorporationYou TECH | $8.3B | 73.97x | +164.0% | $0.70 |
 BioMarin Pharmaceutical Inc. BMRN | $10.9B | 32.67x | +16.6% | $1.82 |
 Caris Life Sciences, Inc. CAI | $4.8B | N/A | — | -$0.32 |
 Corcept Therapeutics Incorporated CORT | $8.0B | 36.27x | +29.4% | $0.96 |
 Exelixis, Inc. EXEL | $13.2B | 15.12x | -46.0% | $2.88 |
 Jazz Pharmaceuticals plc JAZZ | $15.0B | N/A | — | -$5.84 |
 Madrigal Pharmaceuticals, Inc. MDGL | $11.0B | N/A | — | -$12.85 |
Industry Average 3 peers with valid PE | — | 28.02x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 110.41x | $0.47 | +64.4% | |
2024-06-30 FY2024 | 67.18x | $1.07 | +49.4% | |
2023-06-30 FY2023 | 44.98x | $1.81 | -10.0% | |
2022-06-30 FY2022 | 49.97x | $1.73 | -59.8% | |
2021-06-30 FY2021 | 124.26x | $0.91 | +182.4% | |
2020-06-30 FY2020 | 44.00x | $1.50 | -46.5% | |
2019-06-30 FY2019 | 82.30x | $0.64 | +86.1% | |
2018-06-30 FY2018 | 44.24x | $0.84 | -22.0% | |
2017-06-30 FY2017 | 56.74x | $0.52 | +41.3% | |
2016-06-30 FY2016 | 40.14x | $0.70 | +18.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bio-Techne Corporation (TECH) measures how much investors pay for each dollar of the company's trailing earnings. TECH's current PE ratio of 73.97x is calculated by dividing its stock price of $53.28 by its TTM earnings per share of $0.70.
Frequently asked questions
TECH pe ratio · 6 questionsTECH's current PE ratio is 73.97x as of 2026-06-08, based on a stock price of $53.28 and TTM EPS of $0.70. Data sourced from Financial Modeling Prep via TECH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bio-Techne Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08